Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
5-Amino-1MQ is the odd item in a catalog of metabolic research compounds. Almost everything else in the category is a peptide: a chain of amino acids that binds a cell-surface receptor and triggers a signaling cascade. 5-Amino-1MQ is a small organic molecule of 159 g/mol that crosses the plasma membrane and inhibits an intracellular enzyme, nicotinamide N-methyltransferase (NNMT). Its target sits inside the cytosol of the adipocyte rather than on its surface, and the questions researchers ask of it are about enzyme kinetics and metabolite pools rather than receptor occupancy.
That structural difference has practical consequences for how each class is studied, stored, and measured. This article compares the small-molecule and peptide approaches to metabolic research: what NNMT does and why inhibiting it matters, how receptor-targeted peptides such as Cagrilintide and the incretin research compounds differ in mechanism, and what the two classes demand of a laboratory. All the work described is in vitro or in rodent models. Every compound named is supplied for research use only, not for human consumption.
What 5-Amino-1MQ Is and What NNMT Does
Molecular Identity
5-Amino-1MQ is 5-amino-1-methylquinolinium, a methylquinolinium scaffold carrying a primary amine at the 5 position. The cation has the formula C10H11N2+ and a mass of roughly 159.2 g/mol; it is usually supplied as the iodide salt (C10H11IN2, about 286.1 g/mol). It is not a peptide, has no amino acid sequence, and possesses no secondary structure to lose. The primary amine is the feature that matters most: in the 2018 study that characterized this series, Neelakantan, McHardy, Watowich and colleagues showed that methylquinolinium analogs bearing primary amine substitutions were highly permeable in both passive and active membrane assays, and were selective, sparing structurally related SAM-dependent methyltransferases and the NAD+ salvage enzymes.
The Enzyme and Its Two Currencies
NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. The reaction consumes two things a cell values. It spends SAM, the universal methyl donor that also feeds histone methylation and polyamine synthesis, and it removes nicotinamide from the salvage pathway that regenerates NAD+. Where NNMT is highly expressed, as it is in white adipose tissue and liver in obese rodent models, both pools are drawn down at once.
The consequences were established by Kraus and colleagues in 2014, who found Nnmt to be the most strongly reciprocally regulated gene in adipose tissue when comparing Glut4-knockout and Glut4-overexpressing mice. Knocking Nnmt down in white adipose tissue and liver protected mice against diet-induced weight gain by increasing cellular energy expenditure, and raised adipose SAM and NAD+ levels while upregulating the polyamine-flux enzymes ODC and SSAT. Inhibiting the enzyme with a small molecule reproduces this pattern pharmacologically instead of genetically, which is what makes 5-Amino-1MQ a research tool. A 2024 study in diet-induced obese mice reported that a 5-amino-methylquinolinium inhibitor given daily over 28 days limited gains in body weight and fat mass, improved glucose tolerance and insulin sensitivity, and reduced hepatic steatosis markers, together with tissue-distribution data showing exposure in metabolically active tissues. Because NAD+ availability is the shared currency, this line of work overlaps with research on NAD+ precursors and related cofactor compounds.
How Metabolic Research Peptides Work Instead
Receptor Agonism at the Cell Surface
Peptides in the metabolic category act on receptors, not enzymes. Cagrilintide is a 37-residue amylin analog that engages the calcitonin receptor and its AMY heteromers, with hindbrain sites such as the area postrema identified in rodent studies. The incretin research peptides act at class B G protein-coupled receptors: GLP-1 SM at the GLP-1 receptor, and GLP-3 RT at the GLP-1, GIP, and glucagon receptors together. MOTS-c is a different case again: a mitochondrial-derived peptide studied for AMPK activation and folate-cycle interactions, which places it closer to the intracellular metabolic territory that NNMT occupies.
Different Questions, Different Assays
The distinction shapes experimental design. A receptor agonist is characterized by binding affinity, potency at a signaling readout such as cAMP accumulation, receptor selectivity across a related family, and signaling bias. An enzyme inhibitor is characterized by inhibition constants, mechanism (competitive, bisubstrate, or allosteric), selectivity against related enzymes, and cell permeability, since an intracellular target is unreachable without it. Downstream, an NNMT inhibitor is read out through metabolite pools (SAM, NAD+, 1-MNA), whereas a receptor peptide is read out through second messengers and physiological endpoints. Recent NNMT chemistry reflects that focus: work published in 2026 describes non-SAM-mimetic bisubstrate inhibitors developed to improve selectivity and cellular activity, and a 2026 review of the field notes that target engagement and bioavailability, rather than target validity, have been the limiting factors in preclinical inhibitor programs.
5-Amino-1MQ vs Metabolic Peptides: Compared
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | 5-Amino-1MQ | Cagrilintide | GLP-3 RT | MOTS-c |
|---|---|---|---|---|
| Class | Small molecule (methylquinolinium) | Amylin analog peptide | Triple incretin agonist peptide | Mitochondrial-derived peptide |
| Sequence length | Not applicable | 37 amino acids | 39 amino acids | 16 amino acids |
| Approx. molecular weight | ~159 g/mol (cation); ~286 g/mol as iodide salt | ~4,409 Da | ~4,731 Da | ~2,174 Da |
| Target | NNMT enzyme (intracellular) | CTR and AMY receptors (surface) | GLP-1R, GIPR, GCGR (surface) | AMPK pathway (intracellular) |
| Target location | Cytosol | Cell membrane | Cell membrane | Cytosol and nucleus |
| Mechanism studied | Enzyme inhibition | Receptor agonism | Multi-receptor agonism | Metabolic stress signaling |
| Key readouts | SAM, NAD+, 1-MNA levels | cAMP, food intake in rodents | cAMP across three receptors | AMPK phosphorylation |
| Membrane permeability required | Yes | No | No | Yes |
What This Means for Handling
Physical chemistry follows from structure. A lipidated 4.4 kDa peptide can deamidate, oxidize, or aggregate, which is why peptides ship cold, are stored lyophilized below -20 C, and are reconstituted with care to avoid foaming and repeated freeze-thaw cycles; the storage and handling reference covers those constraints. A small quaternary ammonium salt has none of those degradation routes, though it is hygroscopic and light-sensitive in the usual way of fine chemicals. Analytical verification also differs: a peptide is confirmed by HPLC purity and by a mass spectrometry reading that matches its calculated sequence mass, whereas a small molecule is confirmed against a reference standard and characterized by NMR alongside chromatographic purity. The COA reading guide explains which of those numbers appear on a certificate.
Neither class supersedes the other. In metabolic research the two are complementary probes: a receptor agonist tests what happens when an extracellular signal is applied, and an enzyme inhibitor tests what happens when an intracellular reaction is blocked. Laboratories comparing the small-molecule and peptide approaches will find 5-Amino-1MQ listed alongside the metabolic peptides in the research compound catalog.
Frequently Asked Questions
What is 5-Amino-1MQ?
5-Amino-1MQ is 5-amino-1-methylquinolinium, a small molecule of about 159 g/mol (usually supplied as the iodide salt, about 286 g/mol) that inhibits the enzyme nicotinamide N-methyltransferase. It is not a peptide and has no amino acid sequence. In preclinical research it is used as a membrane-permeable tool for probing NNMT activity in adipocytes and liver cells.
How does 5-Amino-1MQ differ from a peptide like cagrilintide?
Cagrilintide is a 37-amino-acid peptide that binds calcitonin-family receptors on the cell surface and triggers signaling from outside the cell. 5-Amino-1MQ is a small molecule that crosses the membrane and blocks an enzyme inside the cytosol. They differ in size by more than an order of magnitude, in target location, in the assays used to characterize them, and in how they must be stored.
What does NNMT do in metabolic research?
NNMT methylates nicotinamide using S-adenosylmethionine as the methyl donor, producing 1-methylnicotinamide. The reaction consumes SAM and diverts nicotinamide away from NAD+ regeneration, so high NNMT activity draws down both pools. Rodent work published in 2014 showed that reducing Nnmt in white adipose tissue and liver raised SAM and NAD+ levels and increased cellular energy expenditure.
Why does membrane permeability matter for 5-Amino-1MQ?
Because its target is intracellular. A compound aimed at a cytosolic enzyme has no effect unless it reaches the cytosol, which is why the 2018 characterization of this series measured permeability in artificial-membrane and Caco-2 assays and highlighted the primary amine substitution that produced it. Peptide agonists face no such requirement, since their receptors sit on the cell surface.
Is 5-Amino-1MQ stored the same way as research peptides?
Not exactly. Lyophilized peptides are held below -20 C, protected from moisture, and reconstituted carefully because they can deamidate, oxidize, or aggregate. 5-Amino-1MQ is a small quaternary ammonium salt without those degradation routes, though normal fine-chemical practice for a hygroscopic, light-sensitive solid still applies.
Are 5-Amino-1MQ and metabolic peptides intended for human use?
No. Both the small molecule and the peptides described here are laboratory materials supplied for research use only, not for human consumption or self-administration. Every finding summarized above comes from cell culture or rodent models.
References and Further Reading
- Kraus and colleagues on Nnmt knockdown in white adipose tissue and liver, cellular energy expenditure, and adipose SAM and NAD+ levels in mice, 2014. PubMed: nicotinamide N-methyltransferase knockdown diet-induced obesity
- Neelakantan, McHardy, Watowich and colleagues on selective, membrane-permeable methylquinolinium NNMT inhibitors in adipocytes and mice, 2018. PubMed: selective membrane-permeable small molecule inhibitors nicotinamide N-methyltransferase
- Babula, Watowich, Neelakantan and colleagues on a 5-amino-methylquinolinium NNMT inhibitor in diet-induced obese mice, including tissue distribution, 2024. PubMed: NNMT inhibition metabolic dysfunction diet-induced obese mice
- Reviews of NNMT as a metabolic research target, covering NAD+ and methyl-donor homeostasis, 2021 to 2025. PubMed: nicotinamide N-methyltransferase metabolic syndrome review
- Structure-based discovery of non-SAM-mimetic bisubstrate NNMT inhibitors, 2026. PubMed: bisubstrate inhibitors nicotinamide N-methyltransferase
- Pharmacological characterization of cagrilintide at calcitonin-family receptors (research code AM833), 2021. PubMed: AM833 calcitonin family receptors agonist
- Preclinical studies of MOTS-c, AMPK signaling, and mitochondrial-derived peptides in metabolic models. PubMed: MOTS-c AMPK mitochondrial-derived peptide metabolism
